Dr Lisa Crowe
Dr Morven Brown
Dr Jan Lecouturier
Professor Alastair Greystoke
Professor Linda Sharp
et al. | “Oh when’s your treatment ending?” “Never!” The unmet needs of cancer patients treated with immuno-, biological and precision therapies: a qualitative interview study | 2024 |
|
Professor Alastair Greystoke
| A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors | 2024 |
|
Iakov Bolnykh
Professor Hamish McAllister-Williams
Professor Alastair Greystoke
Professor Adam Todd
Professor Linda Sharp
et al. | Breast cancer patients with a pre-existing mental illness are less likely to receive guideline-recommended cancer treatment: a systematic review and meta-analysis | 2024 |
|
Professor Alastair Greystoke
Professor Ruth Plummer
Dr Christoph Oing
Dr Pasquale Rescigno
| Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis | 2024 |
|
Professor Alastair Greystoke
| First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study | 2024 |
|
Dr Abi Gault
Dr Linda Hogarth
Dr Kristian Williams
Professor Alastair Greystoke
Professor Neil Rajan
et al. | Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study | 2024 |
|
Professor Alastair Greystoke
| Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors | 2024 |
|
Sarah Rae
Ellie Taylor
Joseph Hoben
Dr Christoph Oing
Professor Alastair Greystoke
et al. | Social determinants of health inequalities in early phase clinical trials in Northern England | 2024 |
|
Dr Ruth Norris
Dr Rosie Dew
Professor Alastair Greystoke
Dr Nicola Cresti
Henry Cain
et al. | Sociodemographic Disparities in HER2+ Breast Cancer Trastuzumab Receipt: An English Population-Based Study | 2024 |
|
Jenny Welford
Professor Alastair Greystoke
| The care of older patients with cancer across the United Kingdom in 2024: A narrative review by the International Society of Geriatric Oncology UK Country Group | 2024 |
|
Professor Gareth Veal
Professor Steve Wedge
Dr Christopher Bacon
Professor Philip Sloan
Professor Alastair Greystoke
et al. | A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer | 2023 |
|
Dr Lisa Crowe
Dr Morven Brown
Professor Alastair Greystoke
Jan Lecouturier
Professor Adam Todd
et al. | Assessing the unmet needs of patients with advanced cancer treated by biological and precision therapies: protocol for TARGET, a mixed methods study | 2023 |
|
Dr Ruth Norris
Dr Liz Fuller
Professor Alastair Greystoke
Professor Adam Todd
Professor Linda Sharp
et al. | OP41 Routes to diagnosis in lung cancer – do socio-demographics matter? An English population-based study | 2023 |
|
Dr Ruth Norris
Professor Alastair Greystoke
Professor Adam Todd
Professor Linda Sharp
| OP42 Socio-economic inequalities in novel NSCLC treatments during the era of tumour biomarker guided therapy: a population-based cohort study | 2023 |
|
Sarah Rae
Dr Linda Hogarth
Alison Bridgewood
Lisa Brown-Schofield
Dr Saira Bashir
et al. | Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders | 2023 |
|
Dr Ruth Norris
Dr Rosie Dew
Professor Alastair Greystoke
Professor Adam Todd
Professor Linda Sharp
et al. | Socio-economic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker Guided Therapy: A Population-based Cohort Study in a Publicly Funded Healthcare System | 2023 |
|
Jakub Chmelo
Professor Alexander Phillips
Professor Alastair Greystoke
Dr Sarah Charman
Dr Leah Avery
et al. | A feasibility trial of prehabilitation before oesophagogastric cancer surgery using a multi-component home-based exercise programme: the ChemoFit study | 2022 |
|
Dr Matthew Cooper
Jakub Chmelo
Dr Rhona Sinclair
Dr Sarah Charman
Dr Kate Hallsworth
et al. | Exploring factors influencing uptake and adherence to a home-based prehabilitation physical activity and exercise intervention for patients undergoing chemotherapy before major surgery (ChemoFit): a qualitative study | 2022 |
|
Professor Alastair Greystoke
| Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE | 2022 |
|
Dr Ruth Norris
Professor Adam Todd
Professor Alastair Greystoke
Professor Linda Sharp
| OA01.05 Socio-economic Inequalities in NSCLC Treatment During the Era of Tumour Biomarker Guided Therapy: A Population-based Study | 2022 |
|
Professor Alastair Greystoke
| Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study | 2022 |
|
Jenny Welford
Kathryn Hunt
Louise Duncan
Dr Ann Ward
Professor Adam Todd
et al. | The Clinical Frailty Scale can indicate prognosis and care requirements on discharge in oncology and haemato-oncology inpatients: A cohort study. | 2022 |
|
Jakub Chmelo
Professor Alexander Phillips
Professor Alastair Greystoke
Dr Alex Bradshaw
Dr Rhona Sinclair
et al. | Comparison of the effects of FLOT and ECX chemotherapy for oesophagogastric adenocarcinoma on cardiopulmonary reserve | 2021 |
|
Professor Alastair Greystoke
| Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer | 2021 |
|
Jakub Chmelo
Professor Alexander Phillips
Professor Alastair Greystoke
Dr Sarah Charman
Dr Leah Avery
et al. | A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer-the ChemoFit study protocol | 2020 |
|
Ruth Norris
Dr Rosie Dew
Professor Linda Sharp
Professor Alastair Greystoke
Dr Sarah Rice
et al. | Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis | 2020 |
|
Dr Nicola Hannaway
Professor Alastair Greystoke
| CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer | 2020 |
|
Dr Eleanor Smith
Professor Alastair Greystoke
| The care of older cancer patients in the United Kingdom | 2020 |
|
Professor Alastair Greystoke
| The National Lung Matrix Trial of personalised therapy in lung cancer | 2020 |
|
Professor Alastair Greystoke
| 105O - Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study | 2019 |
|
Professor Alastair Greystoke
| 140P - Brigatinib experience on the ALK project | 2019 |
|
Professor Ruth Plummer
Professor Alastair Greystoke
| A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours | 2019 |
|
Alice Coomer
Dr Fiona Black
Professor Alastair Greystoke
Dr Jennifer Munkley
Professor David Elliott
et al. | Alternative splicing in lung cancer | 2019 |
|
Professor Alastair Greystoke
| Implications for UK practice of the use of durvalumab in stage III NSCLC | 2019 |
|
Professor Alastair Greystoke
| Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomalformulation in patients with solid tumours | 2019 |
|
Dr Maziar Navidi
Professor Alexander Phillips
Professor Michael Griffin
Professor Alastair Greystoke
Dr Kate Sumpter
et al. | Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer | 2018 |
|
Dr Joanna Perthen
Dr Tamir Ali
David McCulloch
Maziar Navidi
Professor Alexander Phillips
et al. | Intra- and Interobserver Variability in Skeletal Muscle Measurements using Computed Tomography Images | 2018 |
|
Professor Alastair Greystoke
| ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC) | 2017 |
|
Professor Alastair Greystoke
Dr Noor MD Haris
Professor Ruth Plummer
| SELECT-3: A phase i study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting | 2017 |
|
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al. | A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours | 2016 |
|
Dr Nicola Wyatt
Dr Linda Hogarth
Dianne Turner
Dr Miranda Patterson
Dr David Jamieson
et al. | Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) | 2016 |
|
Dr Sally Hall
Professor Alastair Greystoke
Dr Christopher Jones
Dr Jane Margetts
| Crizotinib in clinical practice: the North East of England's experience | 2016 |
|
Professor Alastair Greystoke
| Development of a circulating miRNA assay to monitor tumor burden: From mouse to man | 2016 |
|
Professor Ruth Plummer
Professor Alastair Greystoke
| SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting | 2016 |
|
Professor Alastair Greystoke
Dr Linda Hogarth
Dr Miranda Patterson
Liam Bolt
Dianne Turner
et al. | The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained | 2016 |
|
Dr Yvette Drew
Professor Alastair Greystoke
Professor Ruth Plummer
| A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM). | 2015 |
|
Professor Ruth Plummer
Professor Alastair Greystoke
| A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors | 2015 |
|
Professor Alastair Greystoke
| An Introduction to Stratified Medicine | 2015 |
|
Professor Alastair Greystoke
| First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014 | 2015 |
|
Professor Vinidh Paleri
Professor Alastair Greystoke
Dr Charles Kelly
| Spindle cell carcinoma of the head and neck region: Treatment and outcomes of 15 patients | 2015 |
|
Dr Manolo D'Arcangelo
Dr Jane Margetts
Professor Alastair Greystoke
| The use of circulating biomarkers in early clinical trials in patients with cancer | 2015 |
|
Professor Alastair Greystoke
| A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors | 2014 |
|
Professor Alastair Greystoke
| Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer | 2014 |
|
Professor Alastair Greystoke
| A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity | 2013 |
|
Professor Alastair Greystoke
| Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: A short communication | 2013 |
|
Professor Alastair Greystoke
| A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients | 2012 |
|
Professor Alastair Greystoke
| Biomarkers of cell death applicable to early clinical trials | 2012 |
|
Professor Alastair Greystoke
| Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer | 2012 |
|
Professor Alastair Greystoke
| How Many Diseases Are Colorectal Cancer? | 2012 |
|
Professor Alastair Greystoke
| Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents | 2012 |
|
Professor Alastair Greystoke
| Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer | 2012 |
|
Mark Leslie
Julieann Sludden
Professor Ruth Plummer
Professor Alastair Greystoke
Professor Alan Calvert
et al. | A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98. | 2005 |
|
